Navigation Links
Thoratec Reports First Quarter 2011 Results
Date:5/3/2011

n the range of $1.35-$1.45.

Gross margin is expected to increase to a range of 67.5 to 68.5 percent on a GAAP basis and 68 to 69 percent on a non-GAAP basis.  

GAAP operating expenses are expected to increase 11 to 15 percent over 2010, while non-GAAP operating expenses are expected to increase approximately 10 to 14 percent versus 2010.  The projected growth reflects the continued investment in our product development and market expansion activities as we move forward with key initiatives.

CONFERENCE CALL/WEBCAST INFORMATION

Thoratec will hold a conference call to discuss its financial results and operating activities for all interested parties at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight Time), today. The teleconference can be accessed by calling (719) 325-2417, passcode 2968035. Please dial in 10-15 minutes prior to the beginning of the call. The webcast will be available via the Internet at http://www.thoratec.com. A replay of the conference call will be available through Tuesday, May 10, via http://www.thoratec.com or by telephone at (719) 457-0820, passcode 2968035.

GAAP TO NON-GAAP RECONCILIATION

Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by the company's products and certain costs of producing those revenues, such as costs of product sales, research and development and selling, general and administrative expenses. We use the following measures, which are not calculated in accordance with Generally Accepted Accounting Principles ("GAAP"): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP other income and expense,  non-GAAP tax rate, non-GAAP net income, non-GAAP net income per diluted share and non-GAAP shares used to compute diluted net income per share. These are non-GAAP fi
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
2. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
3. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
4. Thoratec Reports a 19 Percent Increase in Annual Revenues as Cardiovascular Division Revenues Increase 30 Percent in 2009
5. Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
6. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
7. Thoratec Presentation at Canaccord Adams Conference to be Webcast
8. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
9. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
10. Thoratec Presentation at Piper Jaffray Conference to be Webcast
11. Thoratec Presentation at Raymond James Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Monitoring Market by Product, Component, Application and Geography - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... expected to witness a moderate growth as the markets ... have almost reached the saturation levels. The demand is ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- "North America Orthopedic Braces ... data on the North America Orthopedic Braces and Supports ... dollars, and volume (in units) and average price data ... Knee Braces and Supports , Ankle Braces and ... Upper Extremities Braces and Supports. ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5
... Nov. 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... 30, 2011. Total revenue was $2.6 million and $8.2 ... compared to $1.3 million and $3.8 million for the same periods ... nine months ended September 30, 2011, were $9.0 million and $24.0 ...
... CHICAGO, Nov. 7, 2011 UCB today announced findings ... rates to Cimzia ® (certolizumab pegol) plus methotrexate ... effect on structural joint damage in patients with moderate ... responses were found by both RAPID3 (Routine Assessment of ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 2New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 3New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 4New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 5New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 6New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 7New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 8New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 10New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 12
(Date:7/24/2014)... Pools and beaches are the place to be on hot ... small children, so Amica Insurance is sharing five ... for Disease Control and Prevention, children between the ages of ... and deaths. It’s important to know the best practices for ... the following tips from the American Red Cross:, ...
(Date:7/24/2014)... 2014 (HealthDay News) -- Drinking caffeine may worsen the ... of women as they go through menopause, new survey ... study suggests that limiting caffeine intake may be useful ... and night sweats," said researcher Dr. Stephanie Faubion, director ... in Rochester, Minn. But caffeine -- a stimulant ...
(Date:7/24/2014)... NJ (PRWEB) July 24, 2014 Horizon ... will give one lucky family a rent-free week in ... until August 3, 2014. Don’t miss your chance to ... sweepstakes is open to all New Jersey residents, 25 ... BCBSNJ Facebook page, http://www.facebook.com/HorizonBCBSNJ . , “A ...
(Date:7/24/2014)... working with high-throughput data generated by breast cancer ... a computational method to determine how gene networks ... and as they respond to potential cancer therapy ... with each other in laboratory-grown cells is described ... journal PLOS Computational Biology . , The ...
(Date:7/24/2014)... the Human Papillomavirus Vaccination (HPV) even after becoming ... test results than those who were never vaccinated. ... Transmitted Diseases . , Researchers from Boston ... Medicine conducted a cross-sectional study of 235 women ... testing. HPV status and demographic and behavioral characteristics ...
Breaking Medicine News(10 mins):Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:(Beach) Sands of Time Running out to Enter Horizon Blue Cross Blue Shield of New Jersey’s 2014 “Back to the Boardwalk” Sweepstakes 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... Yale School of Medicine has revealed that diet soda ... recently it was believed that there was a 350% ... soft drinks. In their study published in the recent ... researchers report that the link is unfounded, and warn ...
... due to the use of mobile phones, nor do mobile ... belonging to the Essex University//. The research was headed by ... and asked them to do several memory tests. Participants were ... ,Contrary to previous studies that had claimed that ...
... might reduce the risk of colon cancer have been slashed ... of statins// for cardiovascular disease of 87,000 participants were analyzed ... variety of other cancers in people who took the drugs ... other also had similar results and found no reduced incidence ...
... Bird flu scare in Australia was reported after a man was admitted ... collapsed in the flight// from Taipei and the air port authorities removed ... hospital after he complained of feeling tired and not keeping well. ... is kept in the hospital in total isolation. ,The hospital ...
... used for reducing the cardiovascular risk by lowering the ... it has anti-cancer benefits. Two individual studies by Professor ... Professor Eric Jacobs, American Cancer Society have found that ... disagreed with some researchers reporting the anti-cancer effects of ...
... in 2006 and 2007 on HIV prevention, nearly double the ... to a report published by the // China ... League's Central Committee, the government spent about $12.3 million on ... 2003 and 2004. The government has created short-term and long-term ...
Cached Medicine News:Health News:Soft Drinks May Reduce Esophageal Cancer Risk 2Health News:Counter study: cholesterol drugs no good in preventing colon cancer 2
... The Paradigm Pachymetric Analyzer is designed to ... unique digital signal processing algorithms. During an ... reading if the probe is +1.5 degrees ... of highly accurate results, every time. ,The ...
The CryoSurgery console is the control center for CryoCath's surgical probe. It is a modular system made up of a console control unit and a tank dolly system. The system can be used as a unit or in s...
... has developed a minimally invasive cryocatheter ... It delivers a very high level ... pinpoint site precision, minimal tissue disruption, ... stenosis., ,Freezor Xtra allows physicians to ...
... is a malleable, single-use cryosurgical probe developed ... The probe will ablate cardiac tissue while ... surgical procedure, such as coronary artery bypass ... and/or repair and as part of the ...
Medicine Products: